Trace Life Sciences and Macrocyclics Announce Project Collaboration

Saturday, August 18, 2007 General News J E 4
DALLAS, Aug. 16 Trace Life Sciences and Macrocyclics, Inc.have announced that the two companies will work together on customer projectsthat require labeled bifunctional chelates for radiopharmaceuticalapplications. Macrocyclics currently manufactures bifunctional chelatingagents that safely link radioisotopes to biological targeting molecules suchas antibodies which are valuable tools for imaging and therapy of diseasessuch as cancer. Trace Life Sciences is a leading producer of radioisotopes formedical imaging and therapy. In particular Trace is now providing GMP gradeisotopes such as Cu-64 which promises to have great utility for thefast-growing PET imaging market and Cu-67 which is a key isotope sought afterfor Radioimmunotherapies (RITs). The close proximity of the two companiesprovides the ideal environment for rapid production of labeled products whichcan benefit early-stage clinical development projects.

"We are delighted to have this agreement with our Texas neighbor to helpbring the benefits of both companies together - aside from offeringradioisotopes to industry and research, this partnership with the talentedteam at Macrocyclics gives us another dimension to now offer labeled ligandsand custom synthesis to the research market in one step. Researchers can nowfocus on their work and not on the often cumbersome and difficult labelingtask," said Darren Brown, CEO of Trace Life Sciences.

"The collaboration with Trace Life Sciences will expand the scope of ourofferings to the radiopharmaceutical community - we can now help customersinterested in accelerating advanced research and clinical development programsby providing labeled complexes for imaging and therapeutic applications," saidGarry Kiefer, Director of Operations, Macrocyclics.

This release was issued through eReleases(TM). For more information,visit more information, contact: Meagan Skarbek General Manager, Macrocyclics Tel: 972-250-2248 E-mail: Tracey Lane Vice President, Trace Life Sciences Tel: 940-383-6100 E-mail:

SOURCE Macrocyclics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Selection of Development Candidate Triggers $0.5 M...
Archus Orthopedics, Inc. Completes One Hundred TFA...